Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer.
AuthorsMorgan, Robert David
Clamp, Andrew R
Mitchell, Claire L
Jayson, Gordon C
AffiliationThe Christie NHS Foundation Trust, Manchester, UK
MetadataShow full item record
AbstractINTRODUCTION: Standard of care treatment for women who develop relapsed ovarian cancer includes sequential platinum- and/or paclitaxel-based chemotherapy, with reducing disease-free intervals. Once platinum resistance develops, treatment options become limited and dose-dense regimens may be offered. We report the efficacy and safety of dose-dense cisplatin with gemcitabine chemotherapy for relapsed platinum-resistant ovarian cancer. METHODS: A retrospective analysis of all patients with relapsed, platinum-resistant ovarian, primary peritoneal or fallopian tube cancer treated with cisplatin 35 mg/m2 of body surface area by intravenous infusion with gemcitabine 1000 mg/m2 of body surface area by intravenous infusion on days 1 and 8 of every 21-day treatment cycle between 1 January 2009 and 1 June 2017. RESULTS: Ninety-four eligible patients had received a median of three (range one-eight) prior lines of cytotoxic therapy for relapsed ovarian cancer. Sixty patients (64%) had received ? 1 prior dose-dense chemotherapy regimen. Dose-dense cisplatin with gemcitabine was associated with a median progression-free survival (PFS) of 4.4 months (95% CI 3.6 to 5.3) and overall survival of 7.6 months (95% CI 5.6 to 9.6). The median PFS for dose-dense cisplatin with gemcitabine as first- (n = 34), second- (n = 42), and third-line or later (n = 18) dose-dense therapy was 4.2 (95% CI 3.2 to 5.2), 5.0 (95% CI 3.5 to 6.5), and 4.2 (95% CI 3.3 to 5.1) months respectively. The RECIST objective response rate for first-, second-, and third-line dose-dense cisplatin with gemcitabine was 23%, 14 %, and 7 % respectively. The most common grade 3 - 4 adverse events were thrombocytopenia (20%), anemia (18%), and neutropenia (14%). DISCUSSION: Dose-dense cisplatin with gemcitabine provides modest efficacy whether it is used as a first- or subsequent line of dose-dense chemotherapy to treat relapsed platinum-resistant ovarian cancer and the toxicity is manageable with supportive measures.
CitationMorgan RD, Clamp AR, Zhou C, Saunders G, Mescallado N, Welch R, et al. Dose-dense cisplatin with gemcitabine for relapsed platinum-resistant ovarian cancer. Int J Gynecol Cancer. 2019 Jan 23.
JournalInternational Journal of Gynecological Cancer
- Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
- Authors: Cheng M, Lee HH, Chang WH, Lee NR, Huang HY, Chen YJ, Horng HC, Lee WL, Wang PH
- Issue date: 2019 Nov 29
- Optimal chemotherapy treatment for women with recurrent ovarian cancer.
- Authors: Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P
- Issue date: 2007 Oct
- Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
- Authors: Cohen S, Schwartz M, Dottino P, Beddoe AM
- Issue date: 2019 Apr 25
- Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
- Authors: Liu FS, Ho ES, Hung MJ, Hwang SF, Lu CH, Ke YM
- Issue date: 2004 Aug
- A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer.
- Authors: Le TN, Harvey RE, Kim CK, Brown J, Coleman RL, Smith JA
- Issue date: 2017